Selskabets formål er at drive fabrikation og handel fortrinsvis indenfor medicoteknik samt anden i forbindelse hermed stående virksomhed i ind- og udland Selskabet kan som aktionær og/ eller som interessent ved investering, lån og kreditgivning have interesse i andre selskaber eller virksomheder indenfor samme formål som angivet ovenfor.
| Year | Revenue | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 2025 | 6 mia. | 609 mio. | 7.7 mia. | 6 mia. | 5233 | |
CVR: 63644919
Secondary names: TESTA-LABORATORIUM A/S, AMBU INTERNATIONAL A/S, MEDICOTEST A/S
Compared to 406 companies in Engroshandel med medicinalvarer og sygeplejeartikler
Comparison is based on industry median values
Companies in the same industry and area
CVR 40311408
CVR 41969024
CVR 87148114
CVR 38883437
CVR 43018884
Jakob Koch joined the board
Gry Sahner Gundestrup joined the board
Jesper Domino Rask joined the board
Charlotte Elgaard Bjørnhof left the board
Thomas Bachgaard Jensen left the board
Jakob Koch left the board
AMBU A/S demonstrates a strong financial position with a notable increase in revenue and profit, reporting 6.04 billion DKK in revenue and 609 million DKK in profit for 2025, up from 5.39 billion DKK in revenue and 235 million DKK in profit in 2024. The company's equity stands robust at 6.04 billion DKK, indicating a solid foundation for future growth. However, the lack of detailed financial data for previous years raises concerns about the consistency of its performance. Positioned within the medical supplies industry, AMBU A/S is well-placed to capitalize on ongoing healthcare demands, but its ability to maintain profit margins amidst market fluctuations will be crucial for its trajectory.
AI-generated summary